cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Precision Biosciences Inc
7 own
10 watching
Current Price
$1.17
$0.01
(0.86%)
logo-dtil
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
129.79M
52-Week High
52-Week High
5.1999
52-Week Low
52-Week Low
0.95
Average Volume
Average Volume
0.78M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization129.79M
icon52-Week High5.1999
icon52-Week Low0.95
iconAverage Volume0.78M
iconDividend Yield--
iconP/E Ratio--
What does the Precision Biosciences Inc do?
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More
How much money does Precision Biosciences Inc make?
News & Events about Precision Biosciences Inc.
Business Wire
21days ago
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and...
Business Wire
24days ago
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Companys CMC processes and...
Business Wire
1month ago
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel (azer-cel...
Business Wire
2 months ago
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the companys lead CD19 candidate...
Business Wire
3 months ago
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral...
Frequently Asked Questions
Frequently Asked Questions
What is Precision Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Precision Biosciences Inc shares?
plus_minus_icon
How can I buy Precision Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Precision Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Precision Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Precision Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Precision Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Precision Biosciences Inc?
plus_minus_icon
What percentage is Precision Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Precision Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.17
$0.01
(0.86%)
logo-dtil
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$4.12
$-0.07 (-1.67 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$2.38
$0.28 (13.33 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$3.44
$-0.10 (-2.69 %)
Gracell Biotechnologies Inc
Gracell Biotechnologies Inc
$2.16
$0.02 (0.93 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$4.12
$-0.07 (-1.67 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$2.38
$0.28 (13.33 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$3.44
$-0.10 (-2.69 %)
Gracell Biotechnologies Inc
Gracell Biotechnologies Inc
$2.16
$0.02 (0.93 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00